A drug born from a golf-course soil sample and honored with a Nobel Prize now finds itself at the center of a quieter, more cautious hope: that ivermectin, long celebrated for defeating parasites that blind and cripple millions, might one day be turned against cancer. Laboratory evidence suggests it can disrupt the machinery of malignant cells, yet the distance between a petri dish and a human body remains one of medicine's most humbling chasms. As early clinical trials begin to ask the right questions, researchers and physicians urge patients to resist the pull of promising-sounding findings
Ivermectin Shows Promise in Lab, But Clinical Evidence for Cancer Treatment Remains Absent
Patients with cancer who delay or replace evidence-based treatments with unproven ivermectin risk disease progression and adverse effects from inappropriate dosing.